ABSTRACT: As over 6 million people are infected with Chagas disease and only limited therapeutic options are available, there is an urgent need for novel drugs. The involvement of cyclic nucleotide phosphodiesterases (PDE) in the lifecycle and biological fitness of a number of protozoan parasites has been described and several of these enzymes are thought to be viable drug targets. Within this context, a PDE-focused library was screened for its ability to affect the viability of Trypanosoma cruzi parasites. 5-(3-(Benzyloxy)-4-methoxyphenyl)-2-isopropyl-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one (4), previously reported as a human PDE4 inhibitor, was identified as a hit. Upon optimization on three positions of the phenylpyrazolone scaffold, 2-isopropyl-5-(4-methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one (34) proved to be the most active compound against intracellular forms of T. cruzi (pIC 50 = 6.4) with a 100-fold selectivity with respect to toxicity toward human MRC-5 cells. Evaluation on different life stages and clinically relevant T. cruzi strains revealed that the phenylpyrazolones are not active against the bloodstream form of the Y strain but show submicromolar activity against the intracellular form of the Y-and Tulahuen strains as well as against the nitro-drug-resistant Colombiana strain. In vitro screening of phenylpyrazolones against TcrPDEB1, TcrPDEC, and TcrCYP51 showed that there was a poor correlation between enzyme inhibition and the observed phenotypic effect. Among the most potent compounds, both TcrCYP51 and non-TcrCYP51 inhibitors are identified, which were both equally able to inhibit T. cruzi in vitro.
■ INTRODUCTION
Trypanosoma cruzi, a protozoan parasite, is the causative agent of Chagas disease. 1 This disease was once only endemic in Latin-America, however as human mobility increases it is now spreading into other areas such as Europe, Australia, NorthernAmerica, and Middle America. 2−5 It is estimated that approximately 6 million people are currently infected worldwide. 6 Of all individuals carrying this infection about 30% will develop a progressive chronic cardiomyopathy and another 10% will develop digestive, neurological, or mixed clinical symptoms. 7 While the current drugs benznidazole (Radanil) (1, Figure  1 ) and nifurtimox (Lampit) (2) are quite effective in curing the disease in its initial acute phase, efficacy of these drugs during the chronic disease phase is much less evident. 8 The recent BENEFIT trial on the efficacy of benznidazole (1) in patients with chronic Chagas disease reported that the cardiac deterioration was not significantly impaired, despite the significantly reduced serum parasitemia. 9 Moreover, besides their limited efficacy in the chronic phase, both benznidazole (1) and nifurtimox (2) exhibit severe side effects, require long drug administration, and are ineffective against naturally resistant T. cruzi strains. 10, 11 Despite these risks and limitations and its relatively high disease burden, the drug discovery pipeline for Chagas disease does not provide high hopes for a novel treatment on a short term notice. 12 Mainly academic groups have been trying to fill this innovation gap, although there are some collaborations with industry in public-private partnerships. 13−15 In this paper, we describe part of the research of the EU-funded, public-private consortium PDE4NPD (www.PDE4NPD.eu), that focuses on 3′5′-cyclic nucleotide phosphodiesterases (PDEs) as targets against a number of neglected tropical diseases. PDEs are enzymes that hydrolyze phosphodiesterase bonds such as those found in the intracellular (IC) cyclic nucleotides cAMP and cGMP and thereby are involved in the control of IC signalling. 16 Level control of the secondary messengers cAMP and cGMP is essential in various cell functions, for example differentiation, proliferation, and regulation of osmotic stress in a variety of cells, including parasites. 17−19 In kinetoplastida, four different PDE families have been identified, namely PDEA-PDED, which show high homology between the different kinetoplastid species. 20 Previously, the effectiveness of targeting parasite PDEs has been shown for Giardia lamblia and the closely related protozoan parasite Trypanosoma brucei. 21−23 An inhibitor of two parasite PDEs TbrPDEB1 and TbrPDEB2, NPD-001 (3, Figure 1 ; also disclosed as a human PDE4 inhibitor), elevated IC cAMP levels, disrupted regulation of the cell cycle, and ultimately lead to death of the trypanosomes. 24, 25 Moreover, the importance of PDEs in controlling cAMP levels and thereby regulating cellular processes such as regulatory volume control in T. cruzi has been reported. 26−28 One of the PDE family members, TcrPDEC, has subsequently been suggested as an antiparasitic drug target. 29 As PDE inhibition seems a viable approach toward new treatments against kinetoplastids, an in-house library of known PDE inhibitors was screened against T. cruzi in phenotypic assays. In this screening effort, the human PDE4 inhibitor (hPDE4 pIC 50 = 6.8) NPD-0583 (4, Figure 1 ), previously also reported by Orrling et al. as TbrPDEB1 inhibitor (pIC 50 = 5.4), was identified as a hit against the IC form of T. cruzi (pIC 50 = 5.0). 21 On the basis of these results, three positions of the core scaffold were selected for optimization: the benzyloxy moiety R 1 , the pyrazolone nitrogen substituent R 2 , and the methoxy moiety on R 3 (5, Figure 2 ).
■ CHEMISTRY
For hit optimization and SAR analysis, we designed a synthetic route that allowed efficient modification at all three positions. Orrling et al. 21 reported a similar route for this chemical class;
however, some small modifications were made to the first three steps.
In the first step, the acid chloride of benzoic acid 6 was formed and subsequently condensed with the separately formed lithium enolate of methylisobutyrate (Scheme 1). The resulting β-keto-ester 7 was used crude for the ring closure with hydrazine to give key intermediate 8 in 89% yield over two steps. With dihydropyrazolone 8 at hand, the first substituent of choice could be introduced on the pyrazolone nitrogen (R 2 ) via an alkylation with the desired aliphatic bromine. These N-alkylated intermediates (9−21, Scheme 1) were used in either a Suzuki reaction to install the final aryl substituent (R 1 ) (22−47, 51−64, Scheme 1) or in a Buchwald reaction to install aliphatic amines (48−50) . The third and final position (R 3 ) could be modified after demethylation of intermediate 11 (5-(3-bromo-4-methoxyphenyl)-2-isopropyl-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one), followed by subsequent O-alkylation. The newly obtained O-alkyl intermediates (66−74, Scheme 1) were used in a Suzuki reaction to install the final aryl substituent (R 1 ), (75−83).
■ PHARMACOLOGY AND PARASITOLOGY
All compounds were initially tested for their trypanocidal activity against IC forms of T. cruzi, Tulahuen CL2, β-galactosidase strain (drug sensitive strain, (discrete typing units, DTU VI)) as well as for cytotoxicity on MRC-5 SV2 cells (human lung fibroblasts). In-depth pharmacological profiling was performed using IC amastigotes from the naturally highly and moderately nitro-drug-resistant Colombiana strain (DTU I) and from the Y-strain (DTU II), respectively. Additionally, bloodstream trypomastigotes (BT) of the Y-strain obtained from infected Swiss Webster mice were used. Toxicity profiling was done using primary cell cultures of mouse embryonic cardiac cells. TcrCYP51 inhibition assays were performed 
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Article using CYP51 (full length) from the Tulahuen strain using the fluorescence based assay reported by Riley et al. 30 The catalytic domains of Tcr(Y)PDEC (aa 270−614) and Tcr(Y)PDEB1 (aa 564−918) were amplified by PCR from full length sequences and cloned (NdeI and XhoI) into the vector pET28a. 31 Protein production and purification of both Tcr(Y)PDE_CDs were performed following the same protocol. Escherichia coli strain BL21(DE3)*pLysS was transformed with either plasmid pET28aTcr(Y)PDEC_270-614 or pET28aTcr(Y)PDEB1_564-918 and the resulting recombinant strains were grown in 2YT medium at 37°C. A typical purification yielded about 10 mg Tcr(Y)PDEC_CD and 7 mg Tcr(Y)PDEB1_CD from a 1 L cell culture. PDE activity assays are performed using the PDELight HTS cAMP phosphodiesterase kit (Lonza, Walkersville, USA).
■ RESULTS AND DISCUSSION
Compounds from an in-house PDE-focused library were screened in vitro for their trypanocidal effect against the IC form of T. cruzi (Tulahuen CL2 strain transfected with β-galactosidase gene) and their toxicity on human lung fibroblasts (MRC-5). NPD-0583 (4) was identified as a "hit" from which the phenyl-pyrazolone scaffold (5, Figure 2 ) was derived for further optimization. As the catechol moiety of NPD-0583 (4) is a chemotype commonly observed in human PDE4 inhibitors, and human PDE off-target activity is preferably avoided, the first analogues synthesized did not contain the 3-benzyloxy moiety. Instead, the phenyl group was attached directly to the pyrazolone-phenyl scaffold, leading to compound 22 (Table 1) , which has a similar activity as NPD-0583 (4) with a pIC 50 of 5.1. Moreover, substituted phenyl analogues (23−32, Table 1 ) showed a similar or improved activity over NPD-0583 (4, Figure 1 ). While introduction of a 2-fluorophenyl (23) led to diminished activity (pIC 50 < 4.2), both the 3-and 4-fluorophenyl analogues (24−25, Table 1) showed a substantial increase in activity over the unsubstituted phenyl (22) with pIC 50 values around 6. Introduction of a 3-and 4-chloro-or methoxyphenyl ring (26−29, Table 1 ) also increased activity compared to the unsubstituted phenyl analogue (22) with pIC 50 values around 5.5. The most active substituted phenyl derivative was the 3-cyanophenyl-substituted compound (30) with a pIC 50 of 6.4, while the 4-cyanophenyl analogue (31, Table 1 ) had an activity of 5.6. Substituting both the 3-and 4-position, as seen with dimethoxyphenyl 32 did not improve activity (pIC 50 = 4.9, Table 1 ).
Introduction of pyridines on the R 1 position led to mixed results. The 2-pyridine analogue 33 (Table 1) showed almost no activity, while the 3-and 4-pyridine substituted phenyldihydropyrazolones (34−35) were amongst the most potent analogues with pIC 50 values of 6.4 and 5.8, respectively. Introduction of a fluorine on the 4-position of the 3-pyridine (36) did not affect the activity, while substitution with larger substituents such as 4-methyl (37), 4-methoxy (38) , and 4-cyano (39) resulted in a 10-fold decrease in potency ( Table 1) . Introduction of a methyl group on the 6-position of the 3-pyridinyl moiety (40) decreased activity even further. Adding a small substituent on the 3-position of 4-pyridines resulted in a significant increase in activity; the 3-fluoro-4-pyridinyl analogue (41, Table 1 ) is for example very active with a pIC 50 of 6.3, while the 3-methyl-4-pyridinyl (42) analogue has a pIC 50 of 6.4, as opposed to 5.8 for the unsubstituted 4-pyridinyl (35) . These activities are similar to 3-pyridinylphenylpyrazolone 34 (pIC 50 = 6.4), the most potent compound in the series obtained so far. Introduction of other heterocycles such as a pyrimidine (43, (44) , isoquinoline (45) , furan (46) , and thiophene (47) generally caused a large decrease in activity, exception being pyrimidine 43 which only showed a minor decrease in activity (pIC 50 
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To extend the SAR on this position, several non-aromatic heterocycles (48−50, Table 1 ) were introduced on the R 1 position, but the activity was 100-fold lower than the most potent hits obtained so far, showing that an aromatic feature is preferred on this position.
In the obtained set of phenyldihydropyrazolones with different R 1 substituents, several compounds show potencies around 6.4 (pIC 50 ). Since 3-pyridinyl 34 (NPD-0227) has the lowest clog P, low MRC-5 toxicity, and does not contain a fluorine moiety that has the potential risk of nucleophilic aromatic substitution, SAR exploration on the R 2 and R 3 position (5, Figure 2 ) was further done using this moiety on the R 1 position. Initially, the N-unsubstituted phenyldihydropyrazolone (51) as well as different sizes of branched and unbranched aliphatic chains (52−58, Table 2 ) were synthesized and evaluated on the R 2 position. While the nonsubstituted compound (51, Table 2 ) is virtually inactive with an pIC 50 of 4.4, adding aliphatic R 2 substituents substantially increased activity. While introduction of a methyl group (52, Table 2 ) resulted only in a minor increase, the N-ethyl substituted dihydropyrazolone (53) showed a 10-fold increase in parasitic activity (pIC 50 = 5.4). This activity was further increased by adding another methyl moiety, as in the Nisopropyl substituted dihydropyrazolone NPD-0227 (34, Table 2 ), which has a pIC 50 of 6.4. Analogues containing larger alkyl groups on the R 2 position, such as cyclopropylmethyl 54, cyclobutylmethyl 55, isopentyl 56, and cyclopentyl 57 all showed submicromolar antiparasitic activity ( Table 2) . Introduction of the larger cycloheptyl (58, Table 2 ) decreased the activity against T. cruzi while increasing the cytotoxicity. Introduction of a polar 2-hydroxyethyl group (59) on the pyrazolone nitrogen did not improve the activity compared to the unsubstituted dihydropyrazolone 51 (Table  2) . Introducing butanenitrile (60) or pentanenitrile (61) led to improved activities compared to the unsubstituted pyrazolone 51 with pIC 50 values of 5.4 and 5.9, respectively. To establish if aromatic moieties are allowed on the R 2 position, three methylpyridines (62−64, Table 2 ) were introduced. The observed activities were substantially higher than for the unsubstituted dihydropyrazolone (51). The 4-pyridinylmethyl (64, pIC 50 = 5.8) showed higher activity than the 2-and 3-pyridinylmethyl analogues (62, 63). However, the antiparasitic activity of the 4-pyridinylmethyl-substituted pyrazolone 64 (pIC 50 = 5.8) was well below the activity of the isopropyl derivative 34. Overall, variations on the R 2 -position did not improve the activity significantly compared to the isopropyl dihydropyrazolone (34, Table 2 ). Although the cyclopropylmethyl (54), cyclobutylmethyl (55), and cyclopentyl (57) dihydropyrazolones reached similar potencies as the isopropyl (34), the mild increase in toxicity observed with these compounds as well as higher clog P values resulted in the decision to continue the SAR exploration on R 3 (5, Figure 2 ) with the N-isopropyl moiety on the R 2 position (34).
The final position that was varied on the phenylpyrazolone scaffold was the R 3 position (5, Figure 2 ). At first, small aliphatic moieties up to 5 carbons (75−79, Table 3 ) were introduced. While the smaller ethyl (75) and isopropyl (76) substituents showed a quite drastic drop in activity compared to the original methyl-substituted phenylpyrazolone (34) (Table 3) , the slightly larger cyclopropylmethyl (77), cyclobutylmethyl (78), and cyclopentyl (79) are equipotent to the methoxy analogue (34) with pIC 50 values around 6.3. Installing the larger benzyl group (80) caused a larger drop in activity (pIC 50 of 5.1).
In order to decrease the log P, several aliphatic moieties with heteroatoms were installed. However, neither acetonitrile (81), tetrahydrofuran (82), or tetrahydropyran (83) moieties proved to provide a positive effect on activity (Table 3) as all these derivatives displayed a pIC 50 of 5.0 or lower. Hence, the methoxy group, already present in the original hit, remains the substituent of choice.
After SAR-investigation on the three selected positions (5, Figure 2 ), the most optimal compound within these series contained a 3-pyridinyl moiety on R 1 , an isopropyl group on the R 2 position, and a methyl substituent on the R 3 position. The most active hit, the cyclopentyl-substituted phenyldihydropyrazolone (57, Table 2), was ∼32 fold more active than the original hit (4, Figure 1 ). Nonetheless, it was decided to continue further studies with the 3-pyridinyl phenyldihydropyrazolone (34, NPD-0227) as it showed a slightly lower cytotoxicity (∼100 fold selectivity) and generally had more favorable physicochemical properties compared to the 
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Article other equipotent analogues. The role of physicochemical properties was further investigated by plotting the T. cruzi pIC 50 's against clog P, clog S, and TPSA. However, correlations were all poor with R 2 's below 0.15 (Table S1 , Figures S1−S3).
■ BIOCHEMICAL EVALUATION OF SELECTED PHENYLDIHYDROPYRAZOLONES
As the hit originated from a PDE-focused library and was a moderately potent human PDE4 and TbrPDEB1 inhibitor, the possibility that these molecules exert their phenotypic effect via T. cruzi PDEs was explored. Additionally, compounds were screened for their activity against TcrCYP51 as the 3-pyridinyl moiety is a common chemotype for this known drug target. 32 Analysis of PDE expression in T. cruzi based on the transcriptome data of Li et al. show that all five trypanosome PDEs (A, B1/B2, C, and D) are expressed in trypamastigotes, next to TcrCYP51. 33 Expression levels of TcrPDEC and TcrCYP51 do not change more than two-fold after in vitro infection of human cells, while the mRNA concentrations of TcrPDEB1 and B2 were significantly (log 2 fold-change > 1; qvalue < 0.05) downregulated during the amastigote developmental stages (Supporting Information Figure S4 ). In epimastigotes (insect stage), only TcrPDEC was upregulated compared to trypomastigotes (log 2 fold-change = 2.7; q-value = 1.7 × 10 −10 ) ( Figure S4 ). 33 As mentioned, PDEB1 and PDEB2 of T. brucei have been shown to be essential for survival of the parasite. 34 While not much is yet known about the role of the T. cruzi PDEB enzymes, its homology with the essential PDEB enzymes of T. brucei led to the hypothesis that TcrPDEB inhibition may be the underlying mechanism of the phenotypic activity of the phenyldihydropyrazolones. Therefore, the TcrPDEB1 catalytic domain was expressed and purified and selected molecules from the phenylpyrazolone series were evaluated for inhibitory potential of this enzyme in an in vitro activity assay ( Figure  3A) . Overall, the activity was very poor; for example, 3-methyl-4-pyridinyl-substituted phenylpyrazolone 42 (pIC 50 T. cruzi = 6.4) inhibited 11% at 10 μM, while NPD-0227 (34, pIC 50 T. cruzi = 6.4) did not show any TcrPDEB1 inhibition at all, making it unlikely that this enzyme is responsible for the observed phenotypic effect.
TcrPDEC was previously reported as a biochemically validated target by King-Keller et al.; hence, a selection of phenylpyrazolones was tested for their inhibition of the activity of the TcrPDEC catalytic domain (a.a. 270−614). 29, 31 Overall, the inhibitory activity of the phenyl-dihydropyrazolones against TcrPDEC-CD proved to be relatively weak ( Figure  3B ). The most potent phenotypic hits show less than 50% inhibition of TcrPDEC-CD at 10 μM. For example, 3-methyl-4-pyridinyl substituted phenylpyrazolone 42 inhibits 49% (pIC 50 T. cruzi = 6.4, Table 1 ) and NPD-0227 (34) only 21% of TcrPDEC-CD activity (pIC 50 T. cruzi = 6.4). The poor correlation between the phenotypic activity and TcrPDEC-CD inhibition of this series suggests that this enzyme is also not a key mediator in the observed phenotypic effect ( Figure 3B ).
Inhibition of TcrCYP51 has previously been shown to lead to antiparasitic effects in vitro and in vivo. 35−37 Yet, the recent posacanozole trial suggests that the azole-based TcrCYP51 inhibitor combined with benznidazole is not able to cure parasitemia. 38 These findings have led to a serious debate on the validity of TcrCYP51 as drug target. 37−44 However, in the posacanozole trial, the used dosage of the TcrCYP51 inhibitor only corresponds to 10−20% of the curative dose in mice. 39, 41 Moreover, the trial also employed a short treatment regimen, 50 ) against phenotypic inhibition on T. cruzi (pIC 50 ). Raw data can be found in Table  S1 . clog P, clog P, and TPSA are calculated using CDD Vault.
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Article whereas it is also known that TcrCYP51 inhibitors are slow trypanocidal compounds. 39, 41, 42 It has been suggested that with the design of specific TcrCYP51 inhibitors, instead of repurposing fungal CYP51 inhibitors, different combination therapies, or longer treatment regimens, TcrCYP51 inhibition still has potential. 37, 41, 42, 45 In order to investigate whether the observed antiparasitic effect of the newly identified hit series is caused by inhibition of TcrCYP51, a selection of inhibitors was screened against this enzyme. Gunatilleke et al. reported commonly observed scaffolds in the screening against TcrCYP51: amongst their top 185 ranked hits, 92 contained a 3-pyridinyl and 67 contained a 4-pyridinyl moiety, which is true for most compounds in the phenylpyrazolone series. 32 Interestingly, two distinct groups are visible in Figure 3C while all compounds show phenotypic activity, one group showed pIC 50 values >6.0 against CYP51, while the other group is virtually inactive. For example, NPD-0227 (34) inhibits TcrCYP51 with a pIC 50 of 6.0 (pIC 50 T. cruzi = 6.4), while 4-fluoro-3-pyridinyl substituted phenylpyrazolone 36 (NPD-0398; pIC 50 T. cruzi = 6.3) has a pIC 50 of 4.0 on this enzyme ( Figure 3C , Table 4 ). Also, compounds 30, 41, and 42 are similarly inactive against TcrCYP51, while still showing a submicromolar potency against T. cruzi.
■ IN-DEPTH IN VITRO PARASITOLOGICAL EVALUATION
Next, several of the most active phenylpyrazolones were tested more in-depth for their antiparasitic action. BT from the Ystrain (DTU II) and IC amastigotes of the Tulahuen, Y and Colombiana strains (DTUs VI, II, and I) were used. 46 All compounds show (sub)micromolar activities against the amastigotes from the Tulahuen strain, but both TcrCYP51 actives (compounds 34, 57, 78, Figure 3C , Table 4 ) as well as the inactives 30, 36 (NPD-0398), 41 and 42 ( Figure 3C , Table  4 ) showed a similar drop in activity between the bloodstream form and the IC forms. Such a difference in phenotypic activity is observed more often and has been hypothesized to be an issue for TcrCYP51 inhibitors. 36, 47 Yet, in the current phenylpyrazolone series this difference in phenotypic activity is also seen for compounds without TcCYP51 inhibitory activity. Since all compounds have similar physicochemical properties (Table 4 ) and will thus have most likely similar cellular penetration, another unidentified mechanism of action is responsible for the observed phenotypic effects.
Screening of NPD-0227 (34) against the IC form of the nitro-drug-resistant strains, the Y and Colombiana showed pIC 50 's of 7.0 and 6.3, respectively (Table S3) . Also, this compound did not present a cardiotoxic profile, leading to high selectivity indexes (SI) when amastigotes from the different strains were assessed inside cardiac cell cultures (Table S3) .
■ CONCLUSIONS
By screening a PDE focused library for anti-T. cruzi compounds, phenyldihydropyrazolone 4 was identified as a starting point for further hit optimization. From this structure, the phenylpyrazolone scaffold (5, Figure 2 ) was derived and optimized at three different positions. Investigation of the R 1 position led to the discovery of 3-pyridinyl-phenyldihydropyrazolone 34 (NPD-0227) as the best in this series, showing a pIC 50 of 6.4 and 100-fold selectivity over human MRC-5 cells and >476-fold selectivity over cardiac cell cultures. Although the SAR investigation on the R 2 and R 3 positions (5, Figure 2) yielded useful SAR data, activities did not improve compared to the initial hit. Screening of a selection of phenylpyrazolones on TcrPDEC and TcrPDEB1 showed low activities and poor correlation with phenotypic inhibition, suggesting that neither of these PDEs is responsible for the observed phenotypic activity. In vitro screening of phenylpyrazolones against TcrCYP51 showed both active and inactive compounds. Parasitic screening of both CYP51 actives (34, 57 and 78) and inactives (30, 36, 41 and 42) indicates that inhibition of this enzyme is not responsible for the observed phenotypic action of this class of compounds. 3-Pyridine 34 (NPD-0227) shows improved phenotypic activity over the currently used drug benznidazole (1) on the IC form of the Tulahuen and Ystrain of T. cruzi (pIC 50 = 6.4 and 7.0 respectively) as well as against the highly nitro-drug-resistant Colombiana strain (pIC 50 = 6.3). The low activity of this series on the bloodstream form will likely prevent full sterile cure. Additional research is needed to improve the activity against the bloodstream form and/or evaluate this class of compounds for combination therapy against T. cruzi.
■ EXPERIMENTAL SECTION BIOLOGY
CYP51 Assay Protocol. Assay was carried out as described in Riley et al. 30 T. cruzi Cellular Assay. BT of the Y strain of T. cruzi were obtained by cardiac puncture of infected Swiss Webster mice, on the parasitemia peak. 48, 49 For the standard in vitro susceptibility assay on IC amastigotes, T. cruzi Tulahuen CL2, β-galactosidase strain (nifurtimox-sensitive), was used. The strain is maintained on MRC-5 SV2 (human lung fibroblast) cells7 in MEM medium, supplemented with 200 mM Lglutamine, 16.5 mM NaHCO 3 , and 5% inactivated fetal calf serum (FCSi). All cultures and assays are conducted at 37°C under an atmosphere of 5% CO 2 .
MRC-5 Cytotoxicity Cellular Assay. MRC-5 SV2 cells, originally from a human diploid lung cell line, were cultivated in MEM, supplemented with L-glutamine (20 mM), 16.5 mM sodium hydrogen carbonate, and 5% FCS. For the assay, 10 4 cells/well were seeded onto the test plates containing the prediluted sample and incubated at 37°C and 5% CO 2 for 72 h. Cell viability was assessed fluorimetrically 4 h after addition of resazurin (excitation 550 nm, emission 590 nm). The results are expressed as percentage reduction in cell viability compared to untreated controls.
Cytotoxicity Assays on Cardiac Cells. Non-infected primary cardiac cell cultures were incubated at 37°C for 48 h with increasing concentrations of each compound diluted in RPMI. Morphology and spontaneous contractibility were evaluated by light microscopy, and cellular viability was determined by PrestoBlue tests. 50 The results are expressed as the difference in reduction between treated and nontreated cells according to the manufacturer instructions and the LC 50 value (minimum concentration that reduces in 50% the cellular viability) was determined. 50 Trypanocidal Activity. BT from Y strain (5 × 10 6 /mL) obtained from the blood of Swiss male infected mice (5 × 10 4 par/animal, ip) at the parasitemia peak were incubated for 24 h at 37°C in RPMI in the presence or absence of 1:3 serial dilutions of the compounds (0−50 μM) for determination of parasite death rates through the direct quantification of live parasites by light microscopy. The EC 50 (minimum compound concentration that reduces 50% of the number of parasites) was calculated. The more promising compounds [EC 50 ≤
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Article benznidazole (1)] were evaluated on IC amastigotes of the Y and Colombiana strains in infected cardiac cell cultures. 48 After 24 h infection (10:1 parasite/cell rate), the cultures were treated for 48 h at 37°C with nontoxic concentrations of the compounds. Following the treatment, the cultures were washed with saline, fixed with Bouin for 5 min, stained with Giemsa, and evaluated by light microscopy. The percentage of infected host cells and the number of parasites per cell were determined for the calculation of the infection index, which represents the multiplication index using these two parameters, and then the pIC 50 values were determined. 49 SI is expressed by the ratio between pLC 50 (toxicity for mammalian cells) and the pIC 50 Protein Purification. Protein purification was performed at 4°C. Cleared lysates were loaded on a 5 mL HisTrap HP column (GE Healthcare) charged with NiSO 4 . Unbound proteins were washed off with buffer A and the protein eluted with buffer A containing 400 mM imidazole and immediately passed through a HiPrep 26/10 desalting column (GE Healthcare) equilibrated with 20 mM Tris HCl, pH 8.0, 100 mM NaCl, and 2 mM DTT. Next, the protein was subjected overnight to Thrombin cleavage (2−10 units per mg of protein) at 4°C. Cleaved material was separated from uncleaved material by passing it through a gravity flow sepharose column charged with NiSO 4 and further purified by ion-exchange chromatography on Q Sepharose (5 mL HiTrap Q HP, GE Healthcare) equilibrated in buffer C (50 mM Tris HCl, pH 8.0, 100 mM NaCl, 1 mM MgCl 2 , and 1 mM DTT). The protein was eluted with a linear gradient from 0 to 100% buffer D (50 mM Tris HCl, pH 8.0, 500 mM NaCl, 1 mM MgCl 2 , and 1 mM DTT) over 20 column volumes. Aggregates were removed by gel filtration on a Superdex 200 Increase 10/ 300 GL (GE Healthcare) equilibrated in 20 mM Tris HCl, pH 7.5, 100 mM NaCl, 1 mM MgCl 2 , and 1 mM DTT. A typical purification yielded about 10 mg Tcr(Y)PDEC_CD and 7 mg Tcr(Y)PDEB1_CDfrom a 1 L cell culture.
TcrPDEB1 and TcrPDEC Activity Assays. PDE activity assays were performed using the PDELight HTS cAMP phosphodiesterase kit (Lonza, Walkersville, USA). The assay is performed at 25°C in nonbinding, low volume 384 wells plates (Corning, Kennebunk, ME, USA). PDE activity measurements (Tcr(Y)PDEC_CD; K m 11.12 μM ± 1.78, Tcr(Y)PDEB1; K m 2.22 μM ± 0,31) are made in "stimulation buffer" (50 mM Hepes, 100 mM NaCl, 10 mM MgCl, 0.5 mM EDTA, 0.05 mg/mL BSA, pH 7.5). For each PDE, the optimal enzyme concentration was determined according to the manufacturers protocol. Single concentration measurements are made at 10 μM inhibitor concentration (Triplo measurements/assay, n = 2). Dose−response curves were made in the range 100 μM to 10 pM (Triplo measurements/assay, n = 3). Compounds were diluted in dimethyl sulfoxide (DMSO) (final concentration 1%). Inhibitor dilutions (2,5 μL) were transferred to the 384-wells plate, 2, 5 μL PDE in stimulation buffer is added and mixed, 5 μL cAMP (at 2 × K m up to 20 μM) is added, and the assay is incubated for 20 min at 300 rpm. The reaction is terminated by addition of 5 μL Lonza Stop Buffer supplemented with 10 μM NPD-0001. Next, 5 μL of Lonza Detection reagent (diluted to 80% with reaction buffer) is added, and the reaction incubated for 10 min, shaking 300 rpm. Luminescence was read with a VICTOR3 luminometer using a 0.1 s/well program.
Relative light units (RLUs) were measured in comparison to the DMSO-only control; NPD-001 was taken along as positive control. The K i values of the inhibitors are represented as the mean of at least three independent experiments with the associated standard error of the mean (SEM).
■ EXPERIMENTAL SECTION CHEMISTRY
Chemicals and reagents were obtained from commercial suppliers and were used without further purification. Anhydrous dimethylformamide (DMF), tetrahydrofuan (THF), and dichloromethane (DCM) were obtained by passing them through an activated alumina column prior to use. Microwave reactions were executed using a Biotage Initiator microwave system. 1 H NMR spectra were recorded on a Bruker AVANCE 250 (250 MHz), Bruker AVANCE 400 (400 MHz), Bruker AVANCE 500 (500 MHz), or Bruker 600 AVANCE (600 MHz) spectrometer. Data are reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, dd = double doublet, t = triplet, dt = double triplet, q = quartet, p = pentet, h = heptet, bs = broad singlet, m = multiplet), and coupling constants (Hz). Chemical shifts are reported in ppm with the natural abundance of deuterium in the solvent as the internal reference (CDCl 3 : δ 7.26, (CD 3 ) 2 SO: δ 2.50). 13 C NMR spectra were recorded on a Bruker AVANCE 500 (126 MHz) or Bruker AVANCE 600 (150 MHz). Chemical shifts are reported in ppm with the solvent resonance resulting from incomplete deuteration as the internal reference (CDCl 3 : δ 77.16 or (CD 3 ) 2 SO: δ 39.52). Systematic names for molecules according to IUPAC rules were generated using the Chemdraw AutoName program. Liquid chromatography−mass spectroscopy (LC−MS) data were gathered using a Shimadzu HPLC/MS workstation with an LC-20AD pump system, SPD-M20A diode array detector, and LCMS-2010 EV mass spectrometer. The column used is an XBridge C18 5 μm column (100 mm × 4.6 mm). Solvents used were the following: solvent B = ACN, 0.1% formic acid; solvent A = water, 0.1% formic acid. The analysis was conducted using a flow rate of 1.0 mL/min, start 5% B, linear gradient to 90% B in 4.5 min, and then 1.5 min at 90% B, linear gradient to 5% B in 0.5 min and then 1.5 min at 5% B, total run time of 8 min. All reported compounds have purities >95%, measured at 254 nm, unless otherwise mentioned. All highresolution mass spectroscopy (HRMS) spectra were recorded on a Bruker micrOTOF mass spectrometer using electron spray ionization (ESI) in positive-ion mode. Column purifications were either carried out automatically using Biotage equipment or manually, using 60−200 mesh silica. Thin-layer chromatography analyses were performed with Merck F254 alumina silica plates using UV visualization. All
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Article reactions were done under an N 2 atmosphere, unless specifically mentioned.
General Methods. General Method A: Synthesis of β-Keto-esters. Benzoic acid 6 (25 g, 108 mmol) was suspended in DCM (50 mL) while cooling to 0°C. Subsequently, oxalyl dichloride (13.7 mL, 162 mmol) and DMF (0.08 mL, 1.08 mmol) were added and the mixture was allowed to warm up to room temperature. The mixture was stirred for 2 h after which volatiles were evaporated. The remaining solids were redissolved in 50 mL of THF. In a separate flask, methyl isobutyrate (18.6 mL, 162 mmol) was stirred in THF (50 mL) at −78°C and a 2 M lithium di-isopropyl amide (LDA) (65 mL, 130 mmol) was added dropwise while maintaining −78°C
. Upon full addition, the mixture was stirred for 45 min after which the acid chloride of 6 in THF was added dropwise, again maintaining the temperature at −78°C. The reaction was allowed to warm up to room temperature after which crude was quenched with water and extracted with diethyl ether. The organic phase was washed twice with water and once with brine. The organic layer was then dried with MgSO 4 , filtered, and evaporated to dryness. The crude was used in the next step without further purification.
General Method B: Ring Closure of β-Keto-esters. Crude keto-ester 7 (25 g, 79 mmol) was dissolved in ethanol (75 mL) and hydrazine hydrate (64%) (38.6 mL, 793 mmol) was added. The reaction was stirred at room temperature for 48 h after which white precipitation was visible. To the stirred solution, 20 mL of water was added to allow further precipitation, after which solids were filtered off. Collected solids were dried in vacuo, yielding the desired product.
General Method C: N-Alkylation of Pyrazolones. Pyrazolone 8 (10 g, 34 mmol) was dissolved in dry DMF (25 mL) and cooled to 0°C. Sodium hydride (60% in mineral oil) (1.48 g, 37 mmol) was added, and the reaction was stirred for 30 min at room temperature after which 2-bromopropane (3.54 mL, 38 mmol) was added. The reaction was stirred for 2 h at 50°C after which the reaction mixture was quenched with 50 mL of water. White solids precipitated after quenching, which were filtered off and washed with water (2 × 25 mL). The white solids were dried in vacuo, yielding the target compound as a white solid. On a small scale (<0.5 g), not all analogues precipitated after quenching, instead a purification over SiO 2 was done.
General Method D: Suzuki Coupling. Pyrazolone 11 (1.0 g, 3.0 mmol) and pyridin-3-ylboronic acid (0.54 g, 4.4 mmol) were charged to a microwave vial after which dimethoxyethane (DME) (12 mL) and 1 M Na 2 CO 3 (8.84 mL, 8.84 mmol) were added. The mixture was degassed with N 2 for 5 min after which Pd(dppf)Cl 2 (120 mg, 0.15 mmol) was added. The reaction was then heated in the microwave for 1 h at 120°C. The reaction mixture was diluted with MTBE and filtered over Celite. The residue was washed with saturated NaHCO 3 (2×) and brine (1×). The organic phase was dried over Na 2 SO 4 , filtered, and concentrated in vacuo to be further purified over SiO 2 using a gradient of 40% EtOAc in heptane toward 60% EtOAc in heptane. The target compound was obtained as a white solid.
General Method E: Buchwald Coupling. Pyrazolone 11 (50 mg, 0.15 mmol), piperidine (0.017 mL, 0.18 mmol), Pd 2 (dba) 3 (13 mg, 0.015 mmol), Xantphos (17 mg, 0.029 mmol), and NatBuO (28 mg, 0.29 mmol) were added to a microwave tube. The mixture was diluted with dry toluene (2 mL) and degassed with N 2 for 5 min. The mixture was heated in the microwave at 130°C for 30 min. The reaction mixture was diluted with MTBE and filtered over Celite. The residue was extracted with 1 M Na 2 CO 3 (2×) and brine (1×) after which the organic phase was dried over Na 2 SO 4 and concentrated in vacuo. The remaining crude was purified over SiO 2 using a gradient from 50% EtOAc in n-heptane toward 100% EtOAc, yielding the desired product as a white solid.
General Method F: Demethylation. Pyrazolone 11 (10 g, 29.5 mmol) was dissolved in dry DCM (50 mL) and mixture was cooled toward −78°C. Subsequently, 1 M BBr 3 in DCM (59 mL, 59 mmol) was added dropwise over approximately 30 min. The dry-ice acetone bath was removed and the mixture allowed to warm toward room temperature and was stirred overnight. The reaction mixture was then quenched and diluted with water and extracted with MTBE. The organic phase was washed with brine (1×) and dried over MgSO 4 . The crude was filtered after which remaining volatiles were evaporated in vacuo. The resulting crude was recrystallized from a DCM/MTBE mixture, yielding the product as a white solid.
General Method G: O-Alkylation of Demethylated Pyrazolones. Pyrazolone 65 (500 mg, 1.5 mmol) was dissolved in dry DMF (5 mL) and Cs 2 CO 3 (1.0 g, 3.1 mmol) was added followed by (bromomethyl)cyclobutane (0.19 mL, 1.7 mmol). The reaction mixture was stirred for 3 h at room temperature after which the mixture was poured in 30 mL of water. The aqueous phase was extracted with EtOAc after which the organic phase was washed twice with water followed by brine (1×). The organic phase was dried over MgSO 4 , filtered, and evaporated to dryness. The resulting crude was purified over SiO 2 using a gradient of 20% EtOAc in heptane toward 50% EtOAc in heptane. Evaporation of pure fractions yielded the desired product as a white solid.
Below the experimental details of key-compounds 7, 8, 11, 34, 65, 67, and 76 are included, which are representative for each reaction step. Details as well as the original spectra of all other compounds can be found in the Supporting Information.
Experimental Data. Methyl 3-(3-Bromo-4-methoxyphenyl)-2,2-dimethyl-3-oxopropanoate (7). Prepared according to general method A. Crude yield: 38 g. Small portion was purified to obtain analysis data. 1 5-(3-Bromo-4-methoxyphenyl)-2-isopropyl-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one (11) . Prepared according to general method C using 2-bromopropane (0.95 mL, 10 mmol) to afford 2.0 g (5.9 mmol, 70%) of the title compound as a white solid. 5-(3-Bromo-4-isopropoxyphenyl)-2-isopropyl-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one (67). Prepared according to general method G using 2-bromopropane (0.16 mL, 1.7 mmol) to afford 510 mg (1.4 mmol, 90%) of the title compound as a white solid. 5-(4-Isopropoxy-3-(pyridin-3-yl)phenyl)-2-isopropyl-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one (76). Prepared according to general method D using pyridin-3-ylboronic acid (87 mg, 0.71 mmol) to afford 162 mg (0.44 mmol, 81%) of the title compound as a transparent oil which solidified over time. 
